速递｜Nature子刊发表先为达埃诺格鲁肽注射液Ⅲ期EECOH-1研究结果

Core Viewpoint - The article discusses the successful results of the phase III clinical trial (EECOH-1) for Enoglutide injection, a GLP-1 receptor agonist developed by Xianweida Biotechnology, highlighting its efficacy in lowering blood sugar and weight in adults with type 2 diabetes [4][7]. Group 1: Clinical Trial Results - The EECOH-1 study involved 211 adult participants with poorly controlled type 2 diabetes after dietary and exercise interventions, conducted across 32 centers in China [7]. - Participants were randomly assigned to receive either Enoglutide injection at doses of 0.6mg or 1.2mg, or a placebo, for 24 weeks, followed by an additional 28 weeks of treatment for the placebo group [7]. - After 24 weeks, both Enoglutide doses significantly reduced HbA1c levels compared to the placebo, with the 1.2mg group achieving a reduction of 2.43% [7]. Group 2: Efficacy and Safety - The 0.6mg and 1.2mg groups showed a significant proportion of patients achieving HbA1c levels below 7.0% and ≤6.5%, with the 1.2mg group reaching an 80.3% success rate for HbA1c < 7.0% [7]. - Enoglutide injection also led to significant weight loss, with reductions of 4.51% and 4.74% from baseline for the 0.6mg and 1.2mg groups, respectively, after 24 weeks [8]. - The treatment improved various cardiovascular metabolic risk indicators and showed good overall safety and tolerability, with most adverse events being mild to moderate [8].